Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
35,509,556
-
Total 13F shares
-
9,386,370
-
Share change
-
+433,833
-
Total reported value
-
$72,410,000
-
Price per share
-
$7.75
-
Number of holders
-
32
-
Value change
-
+$2,199,519
-
Number of buys
-
25
-
Number of sells
-
9
Institutional Holders of AN2 Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ANTX) as of Q2 2022
As of 30 Jun 2022,
AN2 Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ANTX) was held by
32 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,386,370 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., BVF INC/IL, CITADEL ADVISORS LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Avidity Partners Management LP, Monashee Investment Management LLC, BlackRock Inc., VANGUARD GROUP INC, Alyeska Investment Group, L.P., and Woodline Partners LP.
This page lists
32
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.